NEWS

NEWS

NEWS

CEO OF PARAGON BIOSCIENCES ON WHY INNOVATION IN PHARMA IS HARD

June 6, 2019

Jeff Aronin, who is the founder, chairman and CEO of Paragon Biosciences, spoke with Chief Executive about why healthcare is stagnant from an innovation standpoint, the importance in doing meaningful work and more. Read about Jeff Aronin’s experience in big pharma and how it led to a focus on treatments for rare diseases through Paragon Biosciences.

Access the entire interview here:

https://chiefexecutive.net/paragon-biosciences-innovation-hard/

CEO OF PARAGON BIOSCIENCES ON WHY INNOVATION IN PHARMA IS HARD

June 6, 2019

Jeff Aronin, who is the founder, chairman and CEO of Paragon Biosciences, spoke with Chief Executive about why healthcare is stagnant from an innovation standpoint, the importance in doing meaningful work and more. Read about Jeff Aronin’s experience in big pharma and how it led to a focus on treatments for rare diseases through Paragon Biosciences.

Access the entire interview here:

https://chiefexecutive.net/paragon-biosciences-innovation-hard/

CEO OF PARAGON BIOSCIENCES ON WHY INNOVATION IN PHARMA IS HARD

June 6, 2019

Jeff Aronin, who is the founder, chairman and CEO of Paragon Biosciences, spoke with Chief Executive about why healthcare is stagnant from an innovation standpoint, the importance in doing meaningful work and more. Read about Jeff Aronin’s experience in big pharma and how it led to a focus on treatments for rare diseases through Paragon Biosciences.

Access the entire interview here:

https://chiefexecutive.net/paragon-biosciences-innovation-hard/